← All indications
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
Subtype terms (1)
More specific conditions that are subtypes of Diabetes Mellitus, Type 2 in the MeSH hierarchy.
- Diabetes Mellitus, Lipoatrophic
1 drug approved
Drugs by status
Approved for this indication (76)
- alogliptin
- liraglutide
- gemigliptin
- insulin glargine
- fenofibrate
- dapagliflozin
- meglitinides
- vildagliptin
- tolbutamide
- simvastatin
- pyridoxine
- protamine insulin
- teneligliptin
- glimepiride
- troglitazone
- finerenone
- tofogliflozin hydrate
- dorzagliatin
- propolis
- acarbose
- saxagliptin
- subetta
- gliclazide
- mitiglinide
- tirzepatide
- lobeglitazone
- glyburide
- epicatechin
- ertugliflozin
- xoma 358
- +46 more
Phase 4 trials (199)
- candesartan
- risedronate
- sodium chloride
- eicosapentanoic acid
- rifampin
- allisartan isoproxil
- pregabalin
- ezetimibe
- ursodeoxycholic acid
- adalimumab
- centella asiatica
- nebivolol
- olanzapine
- patiromer
- chromium tripicolinate
- testosterone
- captopril
- amlodipine
- rosuvastatin
- denosumab
- zinc dichloride
- prednisone
- suvorexant
- ribavirin
- moringa oleifera
- omega-3 fatty acids
- l-alpha-glycerophosphocholine
- beinaglutide
- trimetazidine
- coptis chinesis
- +169 more
Phase 3 trials (136)
- artichoke
- calcifediol
- bevacizumab
- pitavastatin
- tesaglitazar
- cranberry
- Laminaria Japonica
- aflibercept
- hs-20094
- hepatitis b immune globulin (human)
- hintonia latiflora bark
- oryza sativa
- insulin tregopil
- maridebart cafraglutide
- alirocumab
- dimethyl fumarate
- diacerein
- felodipine
- magnesium
- rivoglitazone
- apabetalone
- chinnavanni kashaya vati
- tecoma stans
- bgm0504
- human fecal microbiota
- paroxetine
- mk0767
- nicotine
- cpl-2009-0031
- rexmyelocel-t
- +106 more
Phase 2 trials (303)
Phase 1 trials (222)
Other trials (233)
- krill oil
- tocilizumab
- perflutren protein-type a microspheres
- lovastatin
- bifidobacterium bifidum
- raspberry
- fenugreek seed
- propionibacterium freudenreichii
- propylformic acid
- potassium
- rocuronium
- mangosteen
- cafestol
- prolycopene
- erythritol
- diadzein
- cheddar cheese
- urea
- apple
- 3-hydroxybutyrate
- polyphenols
- linseed oil
- tofu
- isosorbide
- pea
- mung bean
- sterculia gum
- black currant
- galactooligosaccharide
- adzuki bean
- +203 more
Organizations
Organization Involved with Phase 4 Indications (458)
- George Clinical Pty Ltd
- University of Pavia
- Cornell University
- Merck KGaA
- Samuel Lunenfeld Research Institute
- Sanofi
- Esbjerg Hospital
- People's Liberation Army of China
- Actelion
- Mayo Clinic
- Capital Medical University
- Cedars-Sinai Medical Center
- Sun Yat-Sen University
- University of Toronto
- Dokkyo Medical University
- Hospital Universitario Central de Asturias
- University of Burgundy
- BIRDEM, Dhaka
- University of Victoria
- Vita-Salute University of Milano. Italy
- Kissei Pharmaceuticals
- Korea University
- Chung-Ang University
- Services Hospital, Lahore
- Leadership Sinai Centre for Diabetes
- Emory University
- Dong-A Pharmaceutical
- University of Strasbourg
- Mountain Diabetes and Endocrine Center
- The University of Hong Kong
- +428 more
Organization Involved with Phase 3 Indications (201)
- Biofortis
- Hospital Universitario Arnau de Vilanova de Lleida
- Unidad de Investigacion Medica en Enfermedades Renales
- National Institute on Aging (NIA)
- Northeast Ohio Medical University
- Columbia University
- National Medical Centre Siglo XXI Mexican Institute for Social Security
- Islamic Azad University of Tabriz
- Leadiant Biosciences, Inc.
- University of Regensburg
- Alkermes
- Parexel
- Dynamic Solutions
- Gan and Lee Pharmaceuticals, USA
- University of Parma
- Woman's Hospital, Louisiana
- Jeil Pharmaceutical Co., Ltd.
- SPARC
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- St. Elizabeth's Medical Center of Boston
- Hengrui Therapeutics, Inc.
- Phenomix
- University of Liege
- Chungnam National University
- National Yang-Ming University
- Oramed Pharmaceutical Inc.
- United BioSource Corporation
- Integrium
- Vifor Inc.
- University of Peradeniya
- +171 more
Organization Involved with Phase 2 Indications (266)
- Medicor Research Inc.
- XBiotech, Inc.
- Targacept
- Prosidion Ltd.
- Kyorin Pharma
- ChemoCentryx
- Piramal
- GMP Companies
- University of Tromso
- State University of New York
- Akcea Therapeutics
- Dance Biopharm Inc.
- Pharmalyte Solutions LLC
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Shandong University
- Pauls Stradins Clinical University Hospital
- Pinnacle Research Group
- Bangalore Diabetes Centre
- Spartanburg Medical Research
- Xoma
- Theratechnologies
- Allegheny Health Network
- Tiziana Life Sciences, PLC
- Boston Therapeutics
- General Electric
- Genfit
- Unidad Comunitaria de Salud Familiar Intermedia de Comasagua (UCSFI-Comasagua)
- Meridien Research
- National Center for Complementary and Integrative Health (NCCIH)
- Genexine, Inc.
- +236 more
Organization Involved with Phase 1 Indications (77)
- Wayne State University
- Richmond Pharmacology
- Locemia Solutions ULC
- Dialysis Clinic, Inc.
- Stendhal Americas, S.A.
- Elite Research Institute
- Beckloff Associates, Inc.
- University of New Mexico
- Loders Croklaan
- Sigrid Juselius Foundation
- University of Sarajevo
- University of Tennessee
- Kaneq Bioscience
- Adocia
- Shanghai Xuhui District Central Hospital
- Linear Clinical Research
- Peptron, Inc.
- Davita Clinical Research
- Beijing Dongfang Biotech Co., Ltd.
- Alizé Pharma
- SeaView Research
- Katholieke Universiteit Leuven
- Cellonis Biotechnology Co. Ltd.
- Sandoz
- Sciwind Biosciences APAC CO Pty. Ltd.
- SGS Life Sciences
- Beijing Chinese Medicine Hospital-Pinggu Hospital
- Thetis Pharmaceuticals LLC
- RegenMedTx
- Simbec-Orion
- +47 more
Organization Involved with Other Experimental Indications (200)
- Obafemi Awolowo University
- Government of Saudi Arabia
- Weizmann Institute of Science
- Latis Srl
- Qingpu Central Hospital,Shanghai
- Institut d'Investigacions Biomèdiques August Pi i Sunyer
- Tubitak
- Radiant Research
- Makati Medical Center
- General Mills Inc.
- Shiga Hospital
- Diabetes UK
- Chinese Nutrition Society
- Wageningen University
- Harokopio University
- Beneo GmbH
- Sawada Clinic
- German Institute of Human Nutrition
- National Science Centre, Poland
- District of Columbia Department of Health
- PuNan Hospital, Shanghai
- University of Peloponnese
- Nagahama Red Cross Hospital
- Alpha Therapy Center
- Kohka Public Hospital
- University of California, Davis
- Bogomolets National Medical University
- Leducq Foundation
- Zagazig University
- Proteus Digital Health, Inc.
- +170 more